These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 30344758)

  • 1. Viability of glioblastoma stem cells is effectively reduced by diisothiocyanate-derived mercapturic acids.
    Cwiklowska K; Westhoff MA; Freisinger S; Dwucet A; Halatsch ME; Knippschild U; Debatin KM; Schirmbeck R; Winiarski L; Oleksyszyn J; Wirtz CR; Burster T
    Oncol Lett; 2018 Nov; 16(5):6181-6187. PubMed ID: 30344758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diisothiocyanate-Derived Mercapturic Acids Are a Promising Partner for Combination Therapies in Glioblastoma.
    Xu P; Westhoff MA; Hadzalic A; Debatin KM; Winiarski L; Oleksyszyn J; Wirtz CR; Knippschild U; Burster T
    ACS Omega; 2022 Feb; 7(7):5929-5936. PubMed ID: 35224353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biological activity of diisothiocyanate-derived mercapturic acids.
    Grzywa R; Winiarski Ł; Psurski M; Rudnicka A; Wietrzyk J; Gajda T; Oleksyszyn J
    Bioorg Med Chem Lett; 2016 Jan; 26(2):667-671. PubMed ID: 26639764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-125b inhibitor may enhance the invasion-prevention activity of temozolomide in glioblastoma stem cells by targeting PIAS3.
    Shi L; Wan Y; Sun G; Zhang S; Wang Z; Zeng Y
    BioDrugs; 2014 Feb; 28(1):41-54. PubMed ID: 23857508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. β-escin selectively targets the glioblastoma-initiating cell population and reduces cell viability.
    Harford-Wright E; Bidère N; Gavard J
    Oncotarget; 2016 Oct; 7(41):66865-66879. PubMed ID: 27589691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. microRNA-181d associated with the methylation status of the MGMT gene in Glioblastoma multiforme cancer stem cells submitted to treatments with ionizing radiation and temozolomide.
    Lizarte Neto FS; Rodrigues AR; Trevisan FA; de Assis Cirino ML; Matias CCMS; Pereira-da-Silva G; Peria FM; Tirapelli DPDC; Carlotti CG
    Brain Res; 2019 Oct; 1720():146302. PubMed ID: 31226325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrin matrices enhance the transplant and efficacy of cytotoxic stem cell therapy for post-surgical cancer.
    Bagó JR; Pegna GJ; Okolie O; Hingtgen SD
    Biomaterials; 2016 Apr; 84():42-53. PubMed ID: 26803410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of PI3K signalling increases the efficiency of radiotherapy in glioblastoma cells.
    Hasslacher S; Schneele L; Stroh S; Langhans J; Zeiler K; Kattner P; Karpel-Massler G; Siegelin MD; Schneider M; Zhou S; Grunert M; Halatsch ME; Nonnenmacher L; Debatin KM; Westhoff MA
    Int J Oncol; 2018 Nov; 53(5):1881-1896. PubMed ID: 30132519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
    Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
    J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Curcumin decreases malignant characteristics of glioblastoma stem cells via induction of reactive oxygen species.
    Gersey ZC; Rodriguez GA; Barbarite E; Sanchez A; Walters WM; Ohaeto KC; Komotar RJ; Graham RM
    BMC Cancer; 2017 Feb; 17(1):99. PubMed ID: 28160777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists.
    Liu Z; Jiang X; Gao L; Liu X; Li J; Huang X; Zeng T
    World Neurosurg; 2019 Aug; 128():e468-e477. PubMed ID: 31048057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of invadopodia activity in glioma cells by sublethal doses of irradiation and temozolomide.
    Mao L; Whitehead CA; Paradiso L; Kaye AH; Morokoff AP; Luwor RB; Stylli SS
    J Neurosurg; 2018 Sep; 129(3):598-610. PubMed ID: 29148898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitizer drugs for the treatment of temozolomide-resistant glioblastoma.
    Baritchii A; Jurj A; Soritau O; Tomuleasa C; Raduly L; Zanoaga O; Cernea D; Braicu C; Neagoe I; Stefan Florian I
    J BUON; 2016; 21(1):199-207. PubMed ID: 27061549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A paired comparison between glioblastoma "stem cells" and differentiated cells.
    Schneider M; Ströbele S; Nonnenmacher L; Siegelin MD; Tepper M; Stroh S; Hasslacher S; Enzenmüller S; Strauss G; Baumann B; Karpel-Massler G; Westhoff MA; Debatin KM; Halatsch ME
    Int J Cancer; 2016 Apr; 138(7):1709-18. PubMed ID: 26519239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The novel CXCR4 antagonist, PRX177561, reduces tumor cell proliferation and accelerates cancer stem cell differentiation in glioblastoma preclinical models.
    Gravina GL; Mancini A; Colapietro A; Vitale F; Vetuschi A; Pompili S; Rossi G; Marampon F; Richardson PJ; Patient L; Patient L; Burbidge S; Festuccia C
    Tumour Biol; 2017 Jun; 39(6):1010428317695528. PubMed ID: 28639900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axis.
    Sato A; Sunayama J; Matsuda K; Seino S; Suzuki K; Watanabe E; Tachibana K; Tomiyama A; Kayama T; Kitanaka C
    Stem Cells; 2011 Dec; 29(12):1942-51. PubMed ID: 21957016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impairing temozolomide resistance driven by glioma stem-like cells with adjuvant immunotherapy targeting O-acetyl GD2 ganglioside.
    Fleurence J; Bahri M; Fougeray S; Faraj S; Vermeulen S; Pinault E; Geraldo F; Oliver L; Véziers J; Marquet P; Rabé M; Gratas C; Vallette F; Pecqueur C; Paris F; Birklé S
    Int J Cancer; 2020 Jan; 146(2):424-438. PubMed ID: 31241171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting and Therapy of Glioblastoma in a Mouse Model Using Exosomes Derived From Natural Killer Cells.
    Zhu L; Oh JM; Gangadaran P; Kalimuthu S; Baek SH; Jeong SY; Lee SW; Lee J; Ahn BC
    Front Immunol; 2018; 9():824. PubMed ID: 29740437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-7-5p suppresses stemness and enhances temozolomide sensitivity of drug-resistant glioblastoma cells by targeting Yin Yang 1.
    Jia B; Liu W; Gu J; Wang J; Lv W; Zhang W; Hao Q; Pang Z; Mu N; Zhang W; Guo Q
    Exp Cell Res; 2019 Feb; 375(1):73-81. PubMed ID: 30586549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
    Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
    J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.